Navigation Links
Inflection Biosciences licenses preclinical oncology programs from the CNIO
Date:6/4/2013

Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.

The compounds leverage the CNIO's considerable expertise in drug discovery and comprise a novel pan-PIM kinase inhibitor program and a number of unique multi-targeting kinase inhibitors combining activity on PIM kinase and additional kinases including the phosphoinositide-3 kinase and the mammalian target of rapamycin (PI3K/mTOR) pathway. All molecules have shown good activity in preclinical models, are orally- available with excellent pharmaceutical properties.

Dr María Blasco, Director of CNIO added "It is a great satisfaction for the CNIO to join forces with the experienced team at Inflection Biosciences, allowing us to take full advantage of our ability to innovate cancer treatments."

Dr Michael O'Neill, Co-Founder and Director of Research and Development at Inflection Biosciences commented "Following an extensive global search we are delighted to have secured assets in late preclinical stages of development of this quality and potential and from an organisation recognised internationally for the quality of its cancer research and its drug discovery programs."


'/>"/>

Contact: Press Office
comunicacion@cnio.es
Centro Nacional de Investigaciones Oncologicas (CNIO)
Source:Eurekalert

Page: 1

Related biology news :

1. HUNT Biosciences and SomaLogic collaborate to validate protein biomarkers of cardiovascular risk
2. Amarantus BioSciences to Present at the National Investment Banking Associations (NIBA)122nd Conference in New York City
3. 3-V Biosciences Appoints Douglas I. Buckley, PhD, as Vice President of Biology
4. Althea Technologies & Profectus BioSciences Sign Manufacturing Agreement For Plasmid DNA Production
5. Ben-Gurion U. licenses drug delivery platform for central nervous system diseases to NY biotech firm
6. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
7. Preclinical studies use specialized ultrasound to detect presence of cancer
8. Preclinical study shows potential of new technologies to detect response to cancer therapy earlier
9. AACR news: Paragazole excels in preclinical models of triple-negative breast cancer
10. ESMO 2012 Congress: A path for medical oncology innovations
11. TGen-US Oncology data guides treatment of metastatic triple-negative breast cancer patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2020)... Md. (PRWEB) , ... April 15, 2020 , ... ... cell (hMSC) working cell banks and hMSC bioprocess systems, announces that the Medical ... Year” award at MTEC’s 4th Annual Membership Meeting in March. The Regenerative Medicine ...
(Date:4/14/2020)... NY (PRWEB) , ... April 14, 2020 , ... ... foam bedding and innovative home comfort technologies, announced today its planned donation of ... organizations in need of masks protect against the COVID-19 pandemic. , “At the ...
(Date:4/14/2020)... LINDA, Calif. (PRWEB) , ... April 14, 2020 ... ... website offering premier, interactive virtual events and webinars, continues to provide cutting-edge research ... held, April 21-23, Genetics Virtual Week will feature more than 25 ...
Breaking Biology News(10 mins):
(Date:5/14/2020)... , ... May 12, 2020 , ... ... JCS as the new distribution partner for all personal care ingredients in Russia ... portfolio and DuPont preservative portfolio for personal care. , The GENENCARE®OSMS ...
(Date:5/9/2020)... , ... May 08, 2020 , ... Worldwide Business ... their successful business program on Sunday, May 10, 2020 and Wednesday, May 13, 2020 ... This episode’s exclusive interviews will spotlight key executives from Techolution and ...
(Date:5/1/2020)... YORK (PRWEB) , ... April 30, 2020 , ... ... Awards were announced today, honoring the businesses, policies, projects, and concepts that are ... a revolutionary bioprinter for living cells, which has taken out the top prize ...
(Date:4/22/2020)... ... April 21, 2020 , ... Aniara ... determination of FXIII. , Aniara Diagnostica, a multi-national distributor of diagnostic and research ... highest standards for product quality and cost-efficient delivery. , For Research ...
Breaking Biology Technology: